Core 1: Biospecimen and Translational Pathology Core

核心 1：生物样本和转化病理学核心

• 批准号: 10270229
• 负责人: Yen-Michael S. Hsu
• 金额: $ 27.28万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10270229
• 关键词: Biological; Biological Assay; Biological Response Modifier Therapy; Blood Banks; Blood Cells; Blood Circulation; Body Fluids; Cancer Center; Cells; Characteristics; Clinical; Clinical Informatics; Clinical Pathology; Clinical Research; Clinical Trials; Collaborations; Core Facility; Correlative Study; Cutaneous Melanoma; Data; Databases; Enrollment; Ensure; Environment; Evaluation; Funding; Genotype; Grant; Health Insurance Portability and Accountability Act; Human body; Image; Immune response; Immunofluorescence Immunologic; Immunologic Monitoring; Immunosuppressive Agents; Immunotherapy; Institutes; Laboratories; Lead; Link; Malignant Neoplasms; Medical center; Melanoma Cell; Metadata; Outcome; Pathologic; Pathologist; Pathology; Patients; Peripheral; Phenotype; Process; Protocols documentation; Recording of previous events; Research; Research Personnel; Research Project Grants; Resources; Role; Sampling; Services; Skin Cancer; Specimen; Specimen Handling; Squamous cell carcinoma; Standardization; System; Therapeutic Intervention; Time; Tissue Harvesting; Tissues; Translational Research; Triage; Tumor-Infiltrating Lymphocytes; Tumor-infiltrating immune cells; Universities; Update; Work; base; biobank; cancer immunotherapy; data de-identification; data sharing; design; digital; liquid crystal polymer; melanoma; nano-string; neoplasm registry; neoplastic cell; operation; programs; repository; success

Abstract: Core 1 Core 1 has the responsibility for the procurement, flow and delivery to the SPORE investigators of biological specimens (tissues, tumor cells, tumor-infiltrating immune cells and cells in the peripheral circulation) and for providing clinicopathological annotation for all subjects enrolled in the clinical trials. This is a critical responsibility that requires diverse expertise in specimen handling, pathology and data base operation. For this reason, the Core will be co-directed by Dr. Whiteside, who will lead the specimen biorepository efforts and Dr. Lucas, a pathologist, who will lead the annotation efforts. The two Co-Directors will be assisted by two Co- Investigators: Dr. Hartman with expertise in clinical informatics systems, and Dr. Karunamurthy, a dermatophatologist with expertise in melanoma and skin cancers. The Biorepository and Pathology Core is embedded in the Immunological Monitoring and Cell Products Laboratory (IMCPL), a shared core facility at the Hillman Cancer Center (HCC) with a history of distinguished service to the previous Melanoma and Skin Cancer SPORE and to cancer immunotherapy studies at the Pittsburgh Cancer Institute (now Hillman Cancer Center, HCC) over the past 33 years. In its role as Core 1 for the MSCP SPORE, the IMCPL will support the biotherapy-based research of all projects by performing project-specific serial accrual of specimens prior to, during and post therapeutic interventions. Core 1 will procure and process all body fluids and tissues harvested from melanoma patients enrolled in SPORE studies and provide immunopathological tissue evaluations, including multispectral analysis of tumor-infiltrating immune cells using Vectra Polaris multispectral immunofluorescence imaging and NanoString GeoMx Digital Spatial Profiling (DSP). Core 1 will also assist the SPORE investigators in implementing assays necessary for evaluation of immunologic responses to immune therapies. Core 1 will ensure that all samples it collects are accompanied by annotations that will permit linking laboratory analyses with clinical results. Data and annotations will be stored in the MSCP SPORE research database and will be updated and retrieved for research projects following established HIPAA protocols. We have a long history of collaboration with the MSCP SPORE investigators, and in the context of this SPORE Program, will be entirely dedicated to the support of the clinical and translational research in patients with melanoma or squamous cell carcinoma.

摘要：核心1 核心1负责采购，流量和交付给生物学的孢子调查员 标本（组织，肿瘤细胞，肿瘤浸润的免疫细胞和周围循环中的细胞）和用于 为参加临床试验的所有受试者提供临床病理注释。这是一个关键 需要在标本处理，病理学和数据库操作方面进行多种专业知识的责任。为了这 原因，核心将由Whiteside博士共同指导，Whiteside博士将领导标本生物座席和博士。 病理学家卢卡斯（Lucas）将领导注释工作。两个联合导演将由两个共同指导协助 研究人员：Hartman博士拥有临床信息学系统专业知识，Karunamurthy博士 皮肤科医生在黑色素瘤和皮肤癌方面具有专业知识。生物疗法和病理核心是 嵌入在免疫监测和细胞产品实验室（IMCPL）中，这是一个共享的核心设施 希尔曼癌症中心（HCC），具有杰出服务的历史 匹兹堡癌症研究所的癌症孢子和癌症免疫疗法研究（现为希尔曼癌 中心，HCC）在过去的33年中。在作为MSCP孢子的核心1的角色中，IMCPL将支持 基于生物疗法的所有项目的研究，通过对标本进行特定于项目特定的标本进行计算， 在治疗干预期间和之后。核心1将采购和处理收获的所有体液和组织 来自参加孢子研究并提供免疫病理组织评估的黑色素瘤患者 包括使用Vectra Polaris多光谱对肿瘤浸润的免疫细胞的多光谱分析 免疫荧光成像和纳米弦Geomx数字空间分析（DSP）。核心1也将协助 孢子研究人员在评估免疫反应所必需的实施测定方面 疗法。核心1将确保其收集的所有样品都伴随着注释，这些注释将允许链接 实验室分析具有临床结果。数据和注释将存储在MSCP孢子研究中 数据库并将在既定的HIPAA协议之后对研究项目进行更新和检索。我们 与MSCP孢子调查人员合作有悠久的历史，在此孢子的背景下 计划将完全致力于支持患者的临床和转化研究 黑色素瘤或鳞状细胞癌。